New blood test shows reliable MS activity tracking

Credibility

Interest

Share:2 min read

Key Takeaway

A combined blood test using many proteins gives a reliable, easy-to-interpret signal of short-term disease activity in relapsing-remitting MS.

What They Found

Researchers measured 18 proteins in the blood and combined them into one Disease Activity (DA) score that also used age and sex. The DA score stayed very consistent when people with stable MS were tested again, more so than two single blood markers called NfL and GFAP (these are proteins that can rise when nerve or brain cells are stressed or damaged). They calculated a minimum detectable change (MDC95) of 1.24 units, which is the smallest change in the DA score that likely means a real change rather than just random variation. In a separate group, when a person's DA score went up more than 1.24 units, they were more likely to have active spots on their MRI called gadolinium-enhancing (Gd+) lesions; when the score went down more than 1.24 units, they were less likely to have those lesions. Overall, the multi-protein DA score tracked changes linked to MRI activity better than the single proteins tested, suggesting it could help monitor disease activity over short times.

Who Should Care and Why

People with relapsing-remitting MS should care because this test could help tell if disease activity is changing, similar to how a fuel gauge shows if a car is running low. Caregivers may find it useful because a single number (the DA score) could make it easier to spot real change without needing to interpret many different test results. Doctors and nurses could use the DA score like a trendline, helping decide whether to check MRI scans, change treatments, or watch symptoms more closely. This matters for daily life because knowing whether disease activity is rising can affect choices about work, travel, or starting a new therapy. The test may be most helpful when combined with symptoms and MRI, not as the only reason to change care plans.

Important Considerations

The study size was modest and focused on short-term stability, so results need confirmation in larger, longer studies before this becomes routine care. The DA score shows association with MRI activity but does not itself show where or how much damage occurred, so MRIs and clinical checks still matter. Also, single test results can be influenced by other health issues, so doctors must interpret the DA score in the full context of each person.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Specific Symptoms Early Research

Article Topics:

Relapsing-remitting multiple sclerosisdisease activityglial fibrillary acidic proteinminimum detectable changeneurofilament light chainreliabilityserum biomarkers

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News